Skip to content

Study · Animal study (in vivo) · mouse · 2002

3 results

Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E

Journal of neural transmission. Supplementum1 Jan 2002Cited by 26 (Europe PMC)

PMID12456076 (opens in a new tab)PepBankPUB-12456076
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic Alzheimer's model mice, Cerebrolysin significantly reduced frontal cortex amyloid burden.

    In plain wordsIn transgenic mice, Cerebrolysin reduced amyloid deposits in the frontal cortex.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseFrontal cortex amyloid burden
    Study

    mousen: not reported in source

    mThy1-hAPP751 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    Quantitative computer-aided analysis with anti-amyloid-beta protein (A beta) antibodies, revealed that Cerebrolysin significantly reduced the amyloid burden in the frontal cortex of 5-month-old mice.
    1 context sentence
    Summary · context
    Transgenic (tg) mice expressing mutant human (h) amyloid precursor protein 751 (APP751) cDNA under the Thy-1 promoter (mThy1-hAPP751) were treated for four weeks with this compound and analyzed by confocal microscopy to asses its effects on amyloid plaque formation and neurodegeneration.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic Alzheimer's model mice, Cerebrolysin reduced A beta(1-42) levels.

    In plain wordsIn transgenic mice, Cerebrolysin reduced A beta(1-42) levels.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseA beta(1-42) levels
    Study

    mousen: not reported in source

    mThy1-hAPP751 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Cerebrolysin treatment reduced the levels of A beta(1-42).
    1 context sentence
    Summary · context
    Transgenic (tg) mice expressing mutant human (h) amyloid precursor protein 751 (APP751) cDNA under the Thy-1 promoter (mThy1-hAPP751) were treated for four weeks with this compound and analyzed by confocal microscopy to asses its effects on amyloid plaque formation and neurodegeneration.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In transgenic Alzheimer's model mice, Cerebrolysin ameliorated frontal cortex synaptic alterations.

    In plain wordsIn transgenic mice, Cerebrolysin reduced synaptic abnormalities in the frontal cortex.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseFrontal cortex synaptic alterations
    Study

    mousen: not reported in source

    mThy1-hAPP751 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · four weeksAs given in this study (mouse).

    Source sentences

    Summary
    This was accompanied by amelioration of the synaptic alterations in the frontal cortex of mThy1-hAPP751 tg mice.
    1 context sentence
    Summary · context
    Transgenic (tg) mice expressing mutant human (h) amyloid precursor protein 751 (APP751) cDNA under the Thy-1 promoter (mThy1-hAPP751) were treated for four weeks with this compound and analyzed by confocal microscopy to asses its effects on amyloid plaque formation and neurodegeneration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.